TG Therapeutics Inc. | Ownership
Companies that own TG Therapeutics Inc.
venBio Select Advisor LLC
4,950,031
5.98%
-279,588
2.14%
06/30/2018
RA Capital Management LLC
4,278,796
5.17%
1,806,452
3%
06/30/2018
BlackRock Fund Advisors
3,731,710
4.51%
528,459
0%
06/30/2018
SSgA Funds Management, Inc.
3,712,103
4.48%
593,842
0%
06/30/2018
Fidelity Management & Research Co.
3,566,433
4.3%
-1,162,800
0.01%
06/30/2018
The Vanguard Group, Inc.
2,668,775
3.22%
219,649
0%
06/30/2018
Franklin Advisers, Inc.
2,263,777
2.73%
-128,520
0.02%
06/30/2018
Bridger Management LLC
2,190,085
2.64%
-183,835
1.33%
06/30/2018
Wells Capital Management, Inc.
853,825
1.03%
853,825
0.02%
06/30/2018
Northern Trust Investments, Inc.
755,731
0.91%
125,430
0%
06/30/2018
| Address |
2 Gansevoort Street
New York New York 10014
United States
|
|
Employees
|
- |
| Website |
http://www.tgtherapeutics.com |
| Updated |
07/08/2019 |
| TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. It also involves developing TG-1101 and TGR-1202 therapies targeting hematological malignancies. The company was founded by Michael Sean Weiss and Laurence H. |
